Stemline Therapeutics, Inc.
Class Period: Jan 20, 2017 to Feb 1, 2017
Lead Plaintiff Deadline: Apr 10, 2017
Summary of Case:
A securities class action has been filed against Stemline Therapeutics, Inc. (STML) on behalf of all persons who purchased shares of Stemline Therapeutics, Inc. ("Stemline") (NASDAQ:STML)between January 20, 2017 and February 1, 2017. This case has been filed in the USDC - NY (Southern).
The complaint alleges that during the class period the Company made materially false and/or misleading statements and/or failed to disclose that: (i) a patient had died in the BPDCN Trial from capilliary leak syndrome immediately prior to the Company's stock offering despite consistently stating that capillary leak syndrome was a potential side-effect of SL-401; and (ii) SL-401's safety profile did not remain predictable and manageable over increasing treatment duration, drug exposure, and patient experience as represented by the Defendants.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.